Agios Pharmaceuticals Says Phase 2 Portion Of The Global Rise Up Study Of Mitapivat In Sickle Cell Disease Met Its Primary Endpoint Of Hemoglobin Response For Patients In Both The 50mg And 100mg Twice Daily Mitapivat Arms
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals announced that the Phase 2 portion of the global RISE UP study of Mitapivat in Sickle Cell Disease met its primary endpoint of hemoglobin response for patients in both the 50mg and 100mg twice daily Mitapivat arms.
June 26, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agios Pharmaceuticals' RISE UP study of Mitapivat in Sickle Cell Disease met its primary endpoint, indicating potential success for the drug.
The positive results from the Phase 2 RISE UP study indicate that Mitapivat has the potential to be an effective treatment for Sickle Cell Disease. This could lead to increased demand for the drug and higher revenues for Agios Pharmaceuticals, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100